GlassScriptPhysician profile
Mohamed Shabana
NPI 1497117147
$5,400.07
in general payments reported to CMS, 2019-2025
44 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,474 · 2024: $2,171 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,278 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,277.86 |
| Education | $122.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $915.80 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $839.05 | 2023-2025 | Ubrelvy, Qulipta |
| Livanova USA, INC. | $357.30 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sumitomo Pharma America, INC. | $350.91 | 2023-2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $297.31 | 2023-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $295.02 | 2023-2025 | Xcopri |
| Pfizer INC. | $215.52 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $166.19 | 2024 | Xeomin |
| Eisai INC. | $139.28 | 2024-2025 | |
| Janssen Biotech, INC. | $137.17 | 2025 | |
| Jazz Pharmaceuticals INC. | $133.98 | 2023-2025 | |
| Mdd US Operations, LLC | $133.37 | 2024 | Gocovri |
| Teva Pharmaceuticals USA, INC. | $104.82 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Neurelis, INC. | $103.44 | 2023-2024 | Valtoco |
| Aucta Pharmaceuticals, INC. | $95.66 | 2024-2025 | Motpoly Xr |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $88.73 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $84.80 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Acadia Pharmaceuticals INC | $81.46 | 2023-2025 | Nuplazid |
| Lundbeck LLC | $74.04 | 2024-2025 | Vyepti |
| Averitas Pharma INC. | $73.77 | 2023-2024 | Qutenza |
| Biogen, INC. | $69.16 | 2024-2025 | Skyclarys |
| Catalyst Pharmaceuticals, INC. | $63.11 | 2024 | |
| Axsome Therapeutics, INC. | $46.37 | 2025 | Symbravo |
| Ipsen Biopharmaceuticals, INC | $44.08 | 2023-2024 | Dysport |
| Celgene Corporation | $41.52 | 2023 | Zeposia |
| Tanabe Pharma America, INC. | $41.08 | 2024 | |
| Vanda Pharmaceuticals INC. | $39.02 | 2025 | Ponvory |
| Impel Pharmaceuticals INC. | $38.71 | 2023 | Trudhesa |
| Immedica Pharma US, INC. | $30.99 | 2024 | |
| Genzyme Corporation | $28.96 | 2023 | |
| Boston Scientific Corporation | $25.22 | 2024 | Wavewriter Alpha Prime 16 |
| Horizon Therapeutics Plc | $25.00 | 2023 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $23.96 | 2023 | Andexxa |
| Octapharma USA, INC. | $21.40 | 2025 | Panzyga |
| Life Molecular Imaging LTD | $20.29 | 2024 | Neuraceq |
| Merck Sharp & Dohme LLC | $19.38 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $18.01 | 2023 | Nuedexta |
| Aprecia Pharmaceuticals, LLC | $17.63 | 2023 | Spritam |
| Amgen INC. | $17.36 | 2025 | |
| Kedrion Biopharma, INC. | $17.26 | 2024 | Kedrab, Koate, Gammaked |
| Azurity Pharmaceuticals, INC. | $16.93 | 2024 | Horizant |
| Nevro Corp. | $16.61 | 2023 | Senza |
| Ani Pharmaceuticals, INC. | $16.40 | 2023 | Purified Cortrophin Gel |
| Microtransponder, INC. | $14.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Shabana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.